Botulinum neurotoxin 3D structures: Difference between revisions
Michal Harel (talk | contribs) No edit summary |
Michal Harel (talk | contribs) No edit summary |
||
| Line 21: | Line 21: | ||
**[[3dda]], [[3ddb]] - CbCBN LC + synaptosomal-associated protein 25 peptide + Zn<br /> | **[[3dda]], [[3ddb]] - CbCBN LC + synaptosomal-associated protein 25 peptide + Zn<br /> | ||
**[[3zur]], [[3zus]] - CbCBN LC/synaptosomal-associated protein 25 translocation domain<br /> | **[[3zur]], [[3zus]] - CbCBN LC/synaptosomal-associated protein 25 translocation domain<br /> | ||
**[[2g7n]], [[2ilp]], [[2imb]], [[3qiy]], [[3qiz]], [[3qj0]], [[4hev]], [[2ima]], [[5v8r]], [[6xcb]], [[6xcc]], [[6xce]], [[6xcf]] – CbCBN LC + inhibitor + Zn<br /> | **[[2g7n]], [[2ilp]], [[2imb]], [[3qiy]], [[3qiz]], [[3qj0]], [[4hev]], [[2ima]], [[5v8r]], [[6xcb]], [[6xcc]], [[6xce]], [[6xcf]], [[7n18]] – CbCBN LC + inhibitor + Zn<br /> | ||
**[[3c88]], [[3c89]], [[3c8a]], [[3c8b]], [[3boo]], [[3qw5]], [[3qw6]], [[3qw7]], [[3qw8]], [[3nf3]] – CbCBN LC + inhibitor peptide + Zn<br /> | **[[3c88]], [[3c89]], [[3c8a]], [[3c8b]], [[3boo]], [[3qw5]], [[3qw6]], [[3qw7]], [[3qw8]], [[3nf3]] – CbCBN LC + inhibitor peptide + Zn<br /> | ||
**[[4ks6]], [[4ktx]], [[5v8p]], [[5v8u]] - CbCBN LC (mutant) + inhibitor peptide + Zn<br /> | **[[4ks6]], [[4ktx]], [[5v8p]], [[5v8u]] - CbCBN LC (mutant) + inhibitor peptide + Zn<br /> | ||
**[[3ds9]] – CbCBN LC (mutant) + inhibitor peptide + Zn + Ni<br /> | **[[3ds9]] – CbCBN LC (mutant) + inhibitor peptide + Zn + Ni<br /> | ||
**[[3k3q]] - CbCBN LC + antibody + Zn<br /> | **[[3k3q]] - CbCBN LC + antibody + Zn<br /> | ||
**[[7l6v]], [[7lzp]], [[7m1h]] - CbCBN LC + nanobody + Zn<br /> | |||
*Type A translocation domain residues 547-871 | *Type A translocation domain residues 547-871 | ||
| Line 34: | Line 35: | ||
*Type A receptor-binding or heavy chain domain residues 871-1296 | *Type A receptor-binding or heavy chain domain residues 871-1296 | ||
**[[2vua]], [[3fuo]], [[5tpb]], [[5tpc]], [[5lr0]], [[5mk6]], [[5mk7]], [[6f0o]], [[6f0p]], [[6twp]], [[6two]], [7dvl]] – CbPBN <br /> | **[[2vua]], [[3fuo]], [[5tpb]], [[5tpc]], [[5lr0]], [[5mk6]], [[5mk7]], [[6f0o]], [[6f0p]], [[6twp]], [[6two]], [7dvl]], [[7z5t]], [[8alp]] – CbPBN <br /> | ||
**[[4iqp]] – CbPBN (mutant)<br /> | **[[4iqp]] – CbPBN (mutant)<br /> | ||
**[[7qpt]], [[7qpu]], [[7z5s]], [[8agk]] – CbPBN + oligosaccharide <br /> | |||
**[[2vu9]] – CbPBN + polysaccharide + Mg<br /> | **[[2vu9]] – CbPBN + polysaccharide + Mg<br /> | ||
**[[4jra]], [[5jlv]], [[5moy]], [[6es1]] – CbCBN + synaptic vesicle glycoprotein 2C<br /> | **[[4jra]], [[5jlv]], [[5moy]], [[6es1]] – CbCBN + synaptic vesicle glycoprotein 2C<br /> | ||
| Line 47: | Line 49: | ||
**[[6ui1]], [[6ul6]] – CbCBN + VHH<br /> | **[[6ui1]], [[6ul6]] – CbCBN + VHH<br /> | ||
*'''Type B''' | *'''Type B residues 1-1291''' | ||
**[[7qfq]] – CbCBN (mutant) – Cryo EM<br /> | |||
**[[1s0b]], [[1s0c]], [[1s0d]], [[1s0e]], [[1s0f]], [[1s0g]], [[1epw]] – CbCBN + Zn<br /> | **[[1s0b]], [[1s0c]], [[1s0d]], [[1s0e]], [[1s0f]], [[1s0g]], [[1epw]] – CbCBN + Zn<br /> | ||
**[[6g5f]] – CbCBN + synaptotagmin-1<br /> | **[[6g5f]] – CbCBN + synaptotagmin-1<br /> | ||
| Line 60: | Line 63: | ||
**[[2etf]], [[1f82]] - CbCBN LC + Zn<br /> | **[[2etf]], [[1f82]] - CbCBN LC + Zn<br /> | ||
**[[7na9]], [[7t5f]] - CbCBN LC + Zn + nanobody<br /> | |||
*Type B Light+Heavy Chain translocation domain residues 1-858 | *Type B Light+Heavy Chain translocation domain residues 1-858 | ||
| Line 105: | Line 109: | ||
*Type E | *Type E | ||
**[[7qfp]] – CbCBN – Cryo EM<br /> | |||
**[[3ffz]], [[4zkt]] – CbCBN + Zn<br /> | **[[3ffz]], [[4zkt]] – CbCBN + Zn<br /> | ||
**[[7k7y]], [[7k84]] - CbCBN + VHH<br /> | **[[7k7y]], [[7k84]] - CbCBN + VHH<br /> | ||
**[[7ovw]] – CbPBN + oligosaccharide <br /> | |||
*Type E Light Chain | *Type E Light Chain | ||